Home / Market News / $SNY

$SNY news and market catalysts

The 22 most recent market catalysts affecting $SNY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

22 catalysts 6 high impact 17 bullish 4 bearish Pharmaceuticals
Nov 19, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Receives EU Approval for VaxRabeo Rabies Vaccine
Sanofi announced that its next-generation rabies vaccine, VaxRabeo, has received European Commission approval for both pre-exposure and post-exposure prophylaxis across all age gro…
Nov 19, 2026 Corporate Catalyst Bullish Impact 55
Sanofi Selects Jacobs for New Insulin Manufacturing Facility in Germany
Sanofi has announced Jacobs as the EPCM partner for a new insulin manufacturing facility in Frankfurt. This strategic investment is designed to enhance Sanofi's production capacity…
Nov 19, 2026 Corporate Catalyst Bullish Impact 75
FDA Approves Sanofi's Infilbray for Type 3 Gaucher Disease
Sanofi announced FDA approval for Infilbray (venglustat) for type 3 Gaucher disease. This is a significant positive development for Sanofi as it expands their specialty care portfo…
Nov 16, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Sarclisa
Sanofi has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to facilitate public access for its multiple myeloma drug, Sarclisa (isatuximab), in Canad…
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
Sanofi Enters $1.2 Billion Research and Licensing Agreement with Seawolf Therapeutics
Sanofi has entered a significant research and licensing agreement with Seawolf Therapeutics, potentially worth up to $1.2 billion in milestone payments. This deal is crucial for Sa…
Nov 13, 2026 Corporate Catalyst Bullish Impact 95
Sanofi Acquires Vicebio and Dynavax for $3.4 Billion
Sanofi announced the acquisition of Vicebio and Dynavax for a total of $3.4 billion. This strategic move significantly bolsters Sanofi's vaccine development capabilities and expand…
Nov 13, 2026 Corporate Catalyst Bullish Impact 75
Citi Analysts Update Outlook on Sanofi's Pipeline and Dupixent
Citi analysts raised Sanofi's price target from 78 to 93 euros, signaling a positive short-term outlook based on recent performance. However, they highlighted significant long-term…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
BNP Paribas Upgrades Sanofi to Outperform
BNP Paribas has upgraded its rating on Sanofi from Neutral to Outperform, indicating a more bullish stance on the pharmaceutical company's prospects. This upgrade is accompanied by…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
BNP Paribas Upgrades Sanofi to Outperform
BNP Paribas upgraded Sanofi's stock rating to Outperform from Neutral, indicating a more favorable view of the company's prospects. This upgrade, coupled with a $57 price target, s…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
AlphaValue/Baader Europe Lifts Sanofi Price Target
AlphaValue/Baader Europe has raised its price target for Sanofi, driven by the sustained commercial success of its key immunology biologic, Dupixent. This analyst action signals co…
Oct 30, 2026 Corporate Catalyst Bullish Impact 85
Sanofi Reports Q3 2026 Financial Results and Raises Full-Year Outlook
Sanofi announced strong third-quarter 2026 financial results, including a 14.3% sales increase and a raised full-year outlook for the second time this year. This positive performan…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Initiates Phase 3 Trial for Influenza-COVID-19 Combination Vaccine
Sanofi has initiated a Phase 3 clinical trial for a combination influenza-COVID-19 vaccine, a significant step towards addressing a global market valued at over $10 billion. This a…
Oct 20, 2026 Corporate Catalyst Bullish Impact 85
Sanofi shares are trading higher after the company and Teva reported Phase 2b data showing duvakitug maintained efficacy through 44 weeks in ulcerative colitis and Crohn's disease. Separately, Sanofi announced an mRNA therapeutics collaboration with ScionxBio.
This headline is a significant positive catalyst for Sanofi, driven by strong clinical trial results for a key pipeline asset, duvakitug, in two major inflammatory bowel diseases. …
Oct 15, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications
Sanofi announced a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Dupixent, expanding its coverage to four additional indications: pediatric atopic derma…
Sep 16, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Inaugurates $925M Flu Vaccine Facility In Toronto, Canada To Strengthen Pandemic Preparedness
Sanofi has opened a major new flu vaccine manufacturing facility in Toronto, a $925 million investment partly funded by the Canadian and Ontario governments. This is significant as…
Aug 18, 2026 Corporate Catalyst Bearish Impact 65
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Sanofi (SNY) has withdrawn its European regulatory application for Dupixent to treat moderate-to-severe bullous pemphigoid. This decision was prompted by the European Medicines Age…
Aug 18, 2026 Corporate Catalyst Bearish Impact 55
EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24
Sanofi Winthrop Industrie has formally withdrawn its application to the EMA for Dupixent (dupilumab) to treat moderate-to-severe bullous pemphigoid in adults. This means the drug w…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Sanofi Secures EU Approval For MenQuadfi In Infants From Six Weeks, Backed By Immunogenicity Data From Pivotal MET58 Study
This EU approval for Sanofi's MenQuadfi vaccine in infants significantly expands its addressable market, particularly in a high-value segment. The positive immunogenicity data from…
Jul 30, 2026 Corporate Catalyst Bearish Impact 85
Sanofi shares are trading lower after the company reported Q2 financial results and issued FY26 sales guidance below estimates.
Sanofi's lower-than-expected Q2 results and, more critically, the downward revision of its FY26 sales guidance, are a direct negative catalyst for the company. This suggests challe…
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate
Sanofi's Q2 results show a substantial beat on both adjusted EPS and sales estimates, with EPS up 34.44% year-over-year and sales up 18.98%. This indicates strong underlying busine…
Jul 24, 2026 Corporate Catalyst Bearish Impact 85
Sanofi Drops Dupixent Successor Candidate After Assessing Data
Sanofi's decision to discontinue amlitelimab, a potential successor to its blockbuster drug Dupixent, is a significant negative catalyst. While the drug showed durable response in …
Jul 24, 2026 Corporate Catalyst Neutral Impact 75
Sanofi Discontinues Amlitelimab Development In Atopic Dermatitis, Will Not Submit For Global Regulatory Reviews After Strategic Pipeline Assessment
Sanofi's discontinuation of Amlitelimab for atopic dermatitis is a negative catalyst for the company, as it removes a potential blockbuster drug from its late-stage pipeline. This …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.